

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE	9
Background	9
Objective and Scope.....	9
Selection of Topics for Monographs	10
Data for Monographs	11
The Working Group	11
Working Procedures.....	11
Exposure Data	12
Studies of Cancer in Humans	14
Studies of Cancer in Experimental Animals	17
Other Data Relevant to an Evaluation of Carcinogenicity and Its Mechanisms	20
Summary of Data Reported.....	21
Evaluation.....	23
References	27
GENERAL REMARKS.....	31
THE MONOGRAPHS	
Wood dust.....	35
1. Exposure data	35
1.1 Composition of wood	35
1.1.1 Classification and nomenclature.....	35
1.1.2 Anatomical features.....	38
1.1.3 Cell wall structure and distribution of components of wood.....	41
1.1.4 Chemical components.....	41
(a) Macromolecular components	48
(b) Low-relative-molecular-mass components.....	48
1.2 Wood-related industries and occupations.....	51
1.2.1 Major woodworking processes.....	53
(a) Debarking	53
(b) Sawing	54
(c) Sanding	55

(d) Planing, jointing, moulding and shaping	55
(e) Turning (lathing)	55
(f) Boring (drilling), routing and carving	55
(g) Mortising and tenoning.....	56
(h) Veneer cutting.....	56
(i) Chipping, flaking, hogging and grinding	56
(j) Mechanical defibrating	57
1.2.2 Sawmilling	57
1.2.3 Manufacture of plywood and other boards	59
(a) Plywood manufacture	59
(b) Manufacture of particle-board and related boards	60
(c) Fibre-board manufacture	60
1.2.4 Wooden furniture manufacture and cabinet-making	61
1.2.5 Manufacture of other wood products.....	63
1.2.6 Construction, carpentry and other wood-related occupations	63
(a) The construction industry	63
(b) Maintenance and repair	64
(c) Pattern and model making	65
(d) Wood shop teachers and artists	65
1.3 Analytical methods.....	65
1.3.1 Characterization and measurement of wood dust.....	65
(a) Type of wood.....	66
(b) Airborne dust concentrations.....	66
(c) Particle size distribution	67
(d) Other characteristics of wood dust	68
1.3.2 Chemical analysis of wood constituents.....	68
(a) Extractives	68
(b) Inorganic compounds in ash.....	69
(c) Polysaccharides	69
(d) Lignin	70
1.4 Exposure to wood dust and other agents in the workplace	70
1.4.1 General influences on occupational exposure to wood dust.....	70
1.4.2 Extent of exposure to wood dust	71
1.4.3 Exposure during sawmilling	72
1.4.4 Exposure during the manufacture of plywood and other boards	74
1.4.5 Exposure during wooden furniture manufacture and cabinet-making.....	78
1.4.6 Exposure during the manufacture of other wood products.....	82
1.4.7 Exposure in other wood-related occupations.....	86
1.4.8 Particle size distribution of wood dust in workroom air	88
1.5 Regulations and guidelines.....	93

CONTENTS

v

2. Studies of cancer in humans	94
2.1 Case reports	94
2.2 Descriptive studies	95
2.3 Cohort studies.....	101
2.4 Case-control studies.....	102
2.4.1 Cancer of the nasal cavity and paranasal sinuses	102
(a) Exposure to wood dust	102
(b) Occupational group.....	111
2.4.2 Cancers of other parts of the respiratory system	127
(a) Nasopharyngeal cancer.....	127
(b) Pharyngeal cancer other than cancer of the nasopharynx.....	129
(c) Laryngeal cancer.....	132
(d) Lung cancer	136
2.4.3 Cancers of the lymphatic and haematopoietic system.....	146
(a) Non-Hodgkin's lymphoma.....	146
(b) Hodgkin's disease.....	152
(c) Multiple myeloma	154
(d) Leukaemia	156
2.4.4 Cancers of the digestive tract.....	158
(a) Exposure to wood dust	158
(b) Occupational group.....	164
3. Studies of cancer in experimental animals	165
3.1 Inhalation.....	165
3.1.1 Rat.....	165
3.1.2 Hamster.....	169
3.2 Intraperitoneal injection.....	169
3.3 Administration with known carcinogens or other modifying factors.....	169
3.3.1 Rat.....	169
3.3.2 Hamster.....	170
3.4 Skin application of wood dust extracts.....	171
3.5 Experimental data on wood shavings.....	173
4. Other data relevant to an evaluation of carcinogenicity and its mechanisms.....	173
4.1 Deposition and clearance.....	173
4.1.1 Humans.....	173
4.1.2 Experimental systems.....	173
4.2 Toxic effects	173
4.2.1 Humans	173
(a) Effects on the nose.....	173
(b) Effects on the lung.....	177
(c) Other effects	183
4.2.2 Experimental systems.....	184

4.3 Genetic and related effects	185
4.3.1 Humans.....	185
4.3.2 Experimental systems.....	185
5. Summary of data reported and evaluation.....	191
5.1 Exposure data	191
5.2 Human carcinogenicity data.....	192
5.3 Animal carcinogenicity data.....	193
5.4 Other relevant data	193
5.5 Evaluation	194
6. References.....	194
Formaldehyde.....	217
1. Exposure data	217
1.1 Chemical and physical data.....	217
1.1.1 Nomenclature.....	217
1.1.2 Structural and molecular formulae and relative molecular mass.....	217
1.1.3 Chemical and physical properties of the pure substance	217
1.1.4 Technical products and impurities.....	218
1.1.5 Analysis	218
1.2 Production and use	219
1.2.1 Production.....	219
1.2.2 Use	221
1.3 Occurrence	223
1.3.1 Natural occurrence.....	223
1.3.2 Occupational exposure.....	224
(a) Extent of exposure	224
(b) Manufacture of formaldehyde, formaldehyde-based resins and other chemical products.....	224
(c) Manufacture of wood products and paper	225
(d) Manufacture of textiles and garments	231
(e) Manufacture of metal products, mineral wool and other products	232
(f) Mortuaries, hospitals and laboratories.....	237
(g) Building, agriculture, forestry and other activities	240
1.3.3 Ambient air	242
1.3.4 Residential indoor air.....	242
1.3.5 Other exposures	243
1.4 Regulations and guidelines.....	243
2. Studies of cancer in humans	246
2.1 Case reports	246
2.2 Descriptive studies	246
2.3 Cohort studies.....	246
2.3.1 Professional groups.....	247
2.3.2 Industrial groups	251

2.4 Case-control studies.....	262
2.4.1 Cancers of the nasal cavity, paranasal sinuses, nasopharynx, oropharynx and pharynx (unclassified)	262
2.4.2 Cancers of the lung and larynx	272
2.4.3 Cancers at other sites	275
2.5 Meta-analyses.....	282
3. Studies of cancer in experimental animals	282
3.1 Inhalation.....	282
3.1.1 Mouse	282
3.1.2 Rat.....	284
3.1.3 Hamster.....	289
3.2 Oral administration.....	289
3.3 Skin application.....	292
3.4 Subcutaneous injection.....	292
3.5 Administration with known carcinogens and other modifying factors	292
3.5.1 Mouse	292
3.5.2 Rat.....	293
3.5.3 Hamster.....	293
4. Other data relevant to an evaluation of carcinogenicity and its mechanisms.....	294
4.1 Absorption, distribution, metabolism and excretion	294
4.1.1 Humans.....	294
4.1.2 Experimental systems	295
4.2 Toxic effects	301
4.2.1 Humans	302
(a) Acute effects	302
(b) Chronic effects.....	304
(c) Allergy	308
4.2.2 Experimental systems	308
(a) Acute effects	309
(b) Chronic effects.....	315
(c) Immunotoxicity	319
4.3 Reproductive and developmental effects.....	319
4.3.1 Humans	319
4.3.2 Experimental systems	320
4.4 Genetic and related effects	321
4.4.1 Humans	321
(a) DNA–protein cross-links.....	321
(b) Mutation and allied effects	321
(c) Sperm abnormalities	322
(d) Urinary mutagenicity	323

4.4.2 Experimental systems	323
(a) DNA–protein cross-links	323
(b) Mutation and allied effects	323
(c) Mutational spectra	330
5. Summary of data reported and evaluation	332
5.1 Exposure data	332
5.2 Human carcinogenicity data	333
5.3 Animal carcinogenicity data	334
5.4 Other relevant data	334
5.5 Evaluation	335
6. References	335
APPENDIX 1. SUMMARY TABLE OF GENETIC AND RELATED EFFECTS	365
APPENDIX 2. ACTIVITY PROFILE FOR GENETIC AND RELATED EFFECTS	369
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES	377

NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.